UMA
14.12.2021 11:02:09 CET | Business Wire | Press release
Jabra and UMA have partnered to deliver innovative video conferencing and meeting room solutions, enabling Jabra devices to be managed seamlessly from one place on the UMA dashboard with real-time analytics. With Jabra PanaCast intelligent video conferencing cameras, users can manage meeting room occupancy levels and control room occupancy levels from a desktop, smartphone or meeting room display panel to optimise the use of office space.
The Jabra PanaCast and PanaCast 50’s unique 180-degree field-of-view covers the whole room and generates anonymous room occupancy data. This feeds real-time information into the UMA dashboard, providing insights and analytics. UMA automatically makes a meeting room available to book in the event of a no-show. Rooms can also be auto-booked by simply walking in.
With the shift towards hybrid-working, companies are reviewing their technology investments and office space-utilisation. UMA enables users to manage meeting-room and desk utilisation and device management of audio-visual devices, all from a single pane of glass. Organisations are now able to optimise their facilities and technology infrastructure to create an efficient and safe workplace, compliant with Covid Winter-Plan guidelines.
The combined value-proposition of UMA and Jabra allows customers to realise an improved return on their technology investments through business intelligence and simpler mechanisms to support and maintain their meeting room technology. Users can check Jabra device status, remotely diagnose and fix issues, and push software updates.
Nigel Dunn, Managing Director, EMEA North at Jabra says, “We are thrilled to be teaming up with UMA to deliver a new standard in meeting room solutions for hybrid working. Jabra PanaCast’s data-driven insights and analytics gives a real-time view of how the workplace is being used, enabling companies to improve efficiency and maximise their real estate. It’s now time to start thinking about future-proofing offices and taking conferencing and the meeting booking experience to the next level.”
Nathan Rogers, Head of Channel, UMA says, “I’m looking forward to continuing to build a strong partnership with Jabra. The UMA and Jabra integration will deliver meaningful insights to businesses ensuring they understand how their real estate is being used. UMA delivers a simplified user experience to enable the booking of meeting spaces, and when partnered with the Jabra PanaCast the business has enhanced analytical data at their fingertips. Jabra’s audio experience and smart UC technology working in coalition with our Workplace Software will deliver a game changing advantage to users.”
Working in partnership with our mutual UK and European distributors means the reseller and Integrator customers will get a cohesive approach.”
The Jabra PanaCast is supported on UMA’s platform today, with PanaCast 50 to follow in early 2022.
For more information, please visit: https://www.jabra.co.uk/Business/for-your-platform/uma
About Jabra
Jabra is a world leading brand in audio, video, and collaboration solutions – engineered to empower consumers and businesses. Proudly part of the GN Group, we are committed to letting people hear more, do more, and be more than they ever thought possible. Jabra engineering excellence leads the way, building on 150 years of pioneering work within the GN Group.
This allows us to create integrated tools for contact centres, offices, and collaboration that help professionals work more productively from anywhere; and true wireless headphones and earbuds that let consumers better enjoy calls, music, and media. The GN Group, founded in 1869, operates in 100 countries and delivers innovation, reliability, and ease of use. GN employs 6,500 people and in 2020 reported annual revenue of DKK 13.4bn. The Jabra brand accounts for approx. DKK 8.7bn and employs 1,900 people. GN makes life sound better and is Nasdaq Copenhagen listed. www.jabra.com
About UMA
UMA is an innovative workplace software-as-a-service platform, connecting internet-of-things, audio, video, and collaboration technology and digitising the workplace environment.
Driven by a passion to improve technology user experiences in the workplace UMA enables you to book and manage resources and optimise space and environmental conditions, adapting to the changing needs of the workforce.
UMA was founded in Halifax, Yorkshire, UK and delivers solutions to enterprise and SME customers from all industry verticals across the world.
Find out more and get started with a free trial of UMA at www.askuma.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005063/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
